0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Pulmonary Medicine

Thomas L. Petty, MD
JAMA. 1987;258(16):2267-2269. doi:10.1001/jama.1987.03400160121033.
Text Size: A A A
Published online

In 1987, the prevention of chronic pulmonary disorders remains a major challenge.1 But to organize effective preventive therapy or treatment of early stages of disease, an understanding of disease mechanisms is required. Recent studies indicate that proteolytic and/or oxidative mechanisms insidiously damage alveoli and small airways and finally result in chronic obstructive pulmonary disease (COPD).2 This pathogenetic mechanism has been well established for emphysema associated with inherited α-antiprotease deficiency states,2 and similar pathogenetic processes may be active in adult respiratory distress syndrome3 and lung cancer.

Attempts at therapy have been initiated. Newly completed animal studies, for example, show that emphysema experimentally produced by human elastase derived from polymorphonuclear leukocytes can be ameliorated by intratracheal instillation of an antiprotease, eglin-c, produced by recombinant DNA technology. The antiprotease offered protection with no evidence of bronchial toxic reactions.4 Clinically, augmentation of α-antiprotease levels in antiprotease-deficient individuals has been

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();